Single-dose drug trial aims to wipe out hidden malaria in conflict-hit region
NCT ID NCT06575647
First seen Jan 11, 2026 · Last updated Jun 24, 2026 · Updated 23 times
Summary
This study tested whether giving a single dose of the drug tafenoquine to everyone in three high-risk villages could safely reduce P. vivax malaria. Over 1,200 residents aged 6 months and older took part. The main goal was to check for serious side effects and see if this mass treatment approach is practical in a region with disrupted health services.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shoklo Malaria Research Unit (SMRU)
Mae Sot, Changwat Tak, Thailand
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tafenoquine (a single-dose malaria drug)
What this could lead to
If successful, this approach could help eliminate P. vivax malaria in hard-to-reach communities and prevent resurgence after health service disruptions.
What could go wrong
This is a completed Phase 4 safety and feasibility study, not a large-scale efficacy trial. Results may not apply to other regions, and side effects or incomplete adherence could limit real-world impact.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.